Spotlight on Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®) in the Prevention of Premalignant Genital Lesions, Genital Cancer, and Genital Warts in Women

被引：0
|
作者：
Paul L. McCormack
Elmar A. Joura
机构：
[1] Adis,Department of Obstetrics and Gynaecology, Division of Gynaecologic Oncology
[2] a Wolters Kluwer Business,undefined
[3] Medical University of Vienna,undefined
来源：
BioDrugs | 2011年 / 25卷
关键词：
Human Papilloma Virus; Genital Wart; Seroconversion Rate; Human Papilloma Virus Vaccine; Human Papilloma Virus Type;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Quadrivalent human papilloma virus (HPV) [types 6, 11, 16, 18] recombinant vaccine (Gardasil®; Silgard®) is composed of virus-like particles (VLPs) formed by self-assembly of recombinant L1 capsid protein from each of HPV types 6, 11, 16, and 18. The VLPs are noninfectious, containing no DNA, and are highly immunogenic, inducing high levels of neutralizing antibodies against the particular HPV types when administered to animals or humans. Quadrivalent HPV vaccine is indicated for use from the age of 9 years for the prevention of premalignant genital lesions (cervical, vulvar, and vaginal), cervical cancer, and external genital warts (condyloma acuminata) causally related to certain oncogenic or specific HPV types.
引用
收藏
页码：339 / 343
页数：4
相关论文
共 42 条
  • [21] Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe
    Hartwig, Susanne
    St Guily, Jean Lacau
    Dominiak-Felden, Geraldine
    Alemany, Laia
    de Sanjose, Silvia
    INFECTIOUS AGENTS AND CANCER, 2017, 12
  • [22] Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics
    Skjeldestad, Finn Egil
    Mehta, Vinay
    Sings, Heather L.
    Overness, Torbjorn
    Turpin, Jennifer
    Su, Ling
    Boerckel, Patricia
    Roberts, Christine
    Bryan, Janine
    Jansen, Kathrin U.
    Esser, Mark T.
    Liaw, Kai-Li
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2008, 87 (01) : 81 - 88
  • [23] Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe
    Susanne Hartwig
    Jean Lacau St Guily
    Géraldine Dominiak-Felden
    Laia Alemany
    Silvia de Sanjosé
    Infectious Agents and Cancer, 12
  • [24] Reductions in Human Papillomavirus-Disease Resource Use and Costs with Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccination: The FUTURE Study Economic Evaluation
    Insinga, Ralph P.
    Dasbach, Erik J.
    Allen, Shannon E.
    Carides, GeorgeW.
    Myers, Evan R.
    VALUE IN HEALTH, 2008, 11 (07) : 1022 - 1032
  • [25] Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18
    Villa, Luisa L.
    Ault, Kevin A.
    Giuliano, Anna R.
    Costa, Ronaldo L. R.
    Petta, Carlos A.
    Andrade, Rosires P.
    Brown, Darron R.
    Ferenczy, Alex
    Harper, Diane M.
    Koutsky, Laura A.
    Kurman, Robert J.
    Lehtinen, Matti
    Malm, Christian
    Olsson, Sven-Eric
    Ronnett, Brigitte M.
    Skjeldestad, Finn Egil
    Steinwall, Margareta
    Stoler, Mark H.
    Wheeler, Cosette M.
    Taddeo, Frank J.
    Yu, Jimmy
    Lupinacci, Lisa
    Railkar, Radha
    Marchese, Rocio
    Esser, Mark T.
    Bryan, Janine
    Jansen, Kathrin U.
    Sings, Heather L.
    Tamms, Gretchen M.
    Saah, Alfred J.
    Barr, Eliav
    VACCINE, 2006, 24 (27-28) : 5571 - 5583
  • [26] Human papillomavirus types 16 and 18 vaccine (Cervarix™): A guide to its use in the prevention of cervical cancer
    不详
    Drugs & Therapy Perspectives, 2008, 24 (6) : 5 - 8
  • [27] Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women
    Barr, Eliav
    Gause, Christine K.
    Bautista, Oliver M.
    Railkar, Radha A.
    Lupinacci, Lisa C.
    Insinga, Ralph P.
    Sings, Heather L.
    Haupt, Richard M.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2008, 198 (03) : 261.e1 - 261.e11
  • [28] Clinical Trial Experience With Prophylactic Human Papillomavirus 6/11/16/18 Vaccine in Young Black Women
    Clark, Liana R.
    Myers, Evan R.
    Huh, Warner
    Joura, Elmar A.
    Paavonen, Jorma
    Perez, Gonzalo
    James, Margaret K.
    Sings, Heather L.
    Haupt, Richard M.
    Saah, Alfred J.
    Garner, Elizabeth I. O.
    JOURNAL OF ADOLESCENT HEALTH, 2013, 52 (03) : 322 - 329
  • [29] Immunogenicity and Safety of the Human Papillomavirus 6, 11, 16, 18 Vaccine in HIV-Infected Young Women
    Kahn, Jessica A.
    Xu, Jiahong
    Kapogiannis, Bill G.
    Rudy, Bret
    Gonin, Rene
    Liu, Nancy
    Wilson, Craig M.
    Worrell, Carol
    Squires, Kathleen E.
    CLINICAL INFECTIOUS DISEASES, 2013, 57 (05) : 735 - 744
  • [30] Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine
    Olsson, Sven-Eric
    Villa, Luisa L.
    Costa, Ronaldo L. R.
    Petta, Carlos A.
    Andrade, Rosires P.
    Malm, Christian
    Iversen, Ole-Erik
    Hoye, John
    Steinwall, Margareta
    Riis-Johannessen, Grete
    Andersson-Ellstrom, Agneta
    Elfgren, Kristina
    von Krogh, Geo
    Lehtinen, Matti
    Paavonen, Jorma
    Tamms, Gretchen M.
    Giacoletti, Katherine
    Lupinacci, Lisa
    Esser, Mark T.
    Vuocolo, Scott C.
    Saah, Alfred J.
    Barr, Eliav
    VACCINE, 2007, 25 (26) : 4931 - 4939
12345